Valnoctamide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Valnoctamide
Skeletal formula of valnoctamide
Identifiers
CAS number 4171-13-5 N
PubChem 20140, 36689722 2R,3R, 10313196 2R,3S, 25271745 2S,3R, 12015994 2S,3S
ChemSpider 18974 YesY, 8488661 2R,3S YesY
UNII 3O25NRX9YG YesY
EC number 224-033-7
KEGG D02717 N
MeSH valnoctamide
ChEMBL CHEMBL1075733 YesY
RTECS number YV5950000
ATC code N05CM13
Jmol-3D images Image 1
Image 2
Properties
Molecular formula C8H17NO
Molar mass 143.23 g mol−1
Appearance White crystals
log P 1.885
Pharmacology
Bioavailability 94%
Routes of
administration
  • Intravenous
  • Oral
Metabolism Hepatic
Elimination
half-life
10 hours
Hazards
GHS pictograms The exclamation-mark pictogram in the Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
GHS signal word WARNING
GHS hazard statements H302
EU classification Harmful Xn
R-phrases R22
LD50 760 mg kg−1 (oral, rat)
Related compounds
Related alkanamides Valpromide
Related compounds
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N (verify) (what is: YesY/N?)
Infobox references

Valnoctamide (INN, USAN) has been used in France as a sedative-hypnotic since 1964.[2] It is a structural isomer of valpromide, a valproic acid prodrug; unlike valpromide, however, valnoctamide is not transformed into its homologous acid, valnoctic acid, in vivo.[3]

Indications[edit]

In addition to being a sedative, valnoctamide has been investigated for use in epilepsy since 1969[4] and was still being investigated in 2000[5] and 2003.

It was studied for neuropathic pain in 2005 by Winkler et al., with good results: it had minimal effects on motor coordination and alertness at effective doses, and appeared to be equally effective as gabapentin.[6]

RH Belmaker, Yuly Bersudsky and Alex Mishory started a clinical trial of valnoctamide for prophylaxis of mania in lieu of the much more teratogenic valproic acid or its salts.[7]

Side effects[edit]

The side effects of valnoctamide are mostly minor and include somnolence and the slight motor impairments mentioned above.

Interactions[edit]

Valnoctamide is known to increase through inhibition of epoxide hydrolase the serum levels of carbamazepine-10,11-epoxide, the active metabolite of carbamazepine, sometimes to toxic levels.[8]

Chemistry[edit]

Valnoctamide is a racemic compound with four stereoisomers,[9] all of which were shown to be more effective than valproic acid in animal models of epilepsy and one of which [(2S,3S]-valnoctamide) was considered to be a good candidate by Isoherranen, et al. for an anticonvulsant in August 2003.[10]

References[edit]

  1. ^ "valnoctamide - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 26 March 2005. Identification and Related Records. Retrieved 20 February 2012. 
  2. ^ Harl, F. M. (March 1964). "[Clinical Study Of Valnoctamide On 70 Neuropsychiatric Clinic Patients Undergoing Ambulatory Treatment]". La Presse Médicale (in French) 72: 753–754. PMID 14119722. 
  3. ^ Haj-Yehia, Abdullah; Meir Bialer (August 1989). "Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity". Pharmaceutical Research 6 (8): 683–689. doi:10.1023/A:1015934321764. PMID 2510141. 
  4. ^ Mattos Nda, S. (May 1969). "[Use of Valnoctamide (nirvanil) in oligophrenic erethics and epileptics]". Hospital (Rio J) (in Portuguese) 75 (5): 1701–1704. PMID 5306499. 
  5. ^ Lindekens, H.; Ilse Smolders; Ghous M. Khan; Meir Bialer; Guy Ebinger; Yvette Michotte (November 2000). "In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy". Pharmaceutical Research 17 (11): 1408–1413. doi:10.1023/A:1007559208599. PMID 11205735. 
  6. ^ Winkler, Ilan; Simcha Blotnik; Jakob Shimshoni; Boris Yagen; Marshall Devor; Meir Bialer (September 2005). "Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain". British Journal of Pharmacology 146 (2): 198–208. doi:10.1038/sj.bjp.0706310. PMC 1576263. PMID 15997234. 
  7. ^ RH Belmaker, Yuly Bersudsky, Alex Mishory and Beersheva Mental Health Center (2005). "Valnoctamide in Mania". ClinicalTrials.gov. United States National Institutes of Health. Retrieved 25 February 2006. 
  8. ^ Pisani, F; Fazio, A; Artesi, C; Oteri, G; Spina, E; Tomson, T; Perucca, E (1992). "Impairment of carbamazepine-10, 11-epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects". British Journal of Clinical Pharmacology 34 (1): 85–87. doi:10.1111/j.1365-2125.1992.tb04114.x. PMC 1381382. PMID 1352988. 
  9. ^ Shimon Barel, Boris Yagen, Volker Schurig, Stephan Sobak, Francesco Pisani, Emilio Perucca and Meir Bialer. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Clinical Pharmacology & Therapeutics 61, 442–449 (April 1997) doi:10.1016/S0009-9236(97)90194-6
  10. ^ Isoherranen, Nina; H. Steve White; Brian D. Klein; Michael Roeder; José H. Woodhead; Volker Schurig; Boris Yagen; Meir Bialer (August 2003). "Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy". Pharmaceutical Research 8 (8): 1293–1301. doi:10.1023/A:1025069519218. PMID 12948028.